Efficacy and safety of switching from Eculizumab to Ravulizumab for the maintenance of aHUS remission after kidney transplant: a preliminary experience
Sign Up to like & getrecommendations! Published in 2024 at "Journal of Nephrology"
DOI: 10.1007/s40620-024-02005-7
Abstract: Ravulizumab (ULTOMIRIS™) is a C5-complement monoclonal antibody, engineered from eculizumab by the replacement of four amino-acids, leading to an increased duration of complement inhibition, with a more than fourfold longer half-life compared to its ancestor.… read more here.
Keywords: safety switching; kidney transplant; eculizumab ravulizumab; kidney ... See more keywords
Work Productivity Loss and Quality of Life in Paroxysmal Nocturnal Hemoglobinuria Among Patients Receiving C5 Inhibitors in the United States
Sign Up to like & getrecommendations! Published in 2020 at "Blood"
DOI: 10.1182/blood-2020-142327
Abstract: INTRODUCTION Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, acquired, hematologic disease characterized by chronic complement-mediated hemolysis. Treatment with the C5 inhibitor eculizumab has resulted in a reduction in intravascular hemolysis and improvements in morbidity and… read more here.
Keywords: eculizumab ravulizumab; productivity; patients reported; work productivity ... See more keywords